VWF and hemophilia A: In this ongoing study, ITI with octanate, a VWF-containing FVIII concentrate, provided a rapid, safe, and sustained eradication of FVIII inhibitors and normalization of FVIII pharmacokinetics in 70% of 100 hemophilia A patients with inhibitors and has the potential to reduce the length of ITI treatment and consequently the burden on patients and cost of ITI.